Skip to main content
OpenTrials

Clinical trial condition

Recurrent Primary Peritoneal Carcinoma

Explore clinical trials studying Recurrent Primary Peritoneal Carcinoma. Study availability and eligibility vary by location and protocol.

80 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Primary Peritoneal Carcinoma trial results

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

NCT01145430

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +30 more
Locations
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Mount Sinai Hospital New York, United States
  • Columbia University/Herbert Irving Cancer Center New York, United States
  • Weill Medical College of Cornell University New York, United States
View Trial Details
Completed

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

NCT01264432

Conditions
Abdominal Neoplasms, Adnexal Diseases, Adult Solid Neoplasm, +24 more
Locations
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01039207

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Florida Hospital Orlando Orlando, Florida, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 28 locations
View Trial Details
Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01175343

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442

Conditions
Adenoma, Adnexal Diseases, Borderline Ovarian Clear Cell Tumor, +143 more
Locations
  • Highlands Oncology Group PA - Fayetteville Fayetteville, Arkansas, United States
  • Washington Regional Medical Center - Fayetteville Fayetteville, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
View all 187 locations
View Trial Details
Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT01283035

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Newton-Wellesley Hospital Newton, Massachusetts, United States
View Trial Details
Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT00671788

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Saint Francis Hospital and Medical Center Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Sarasota Memorial Hospital Sarasota, Florida, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +31 more
Locations
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details

Related conditions